Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* is ≥20 years of age.~* has an established diagnosis of MM based on the myeloma diagnostic criteria~* has received at least 1 but not more than 3 prior anti-myeloma regimens and has progressive disease after the most recent treatment regimen~* has adequate organ function~Exclusion Criteria:~* has had a prior allogeneic bone marrow transplant or plans to undergo any type of bone marrow transplantation during the study~* has known hypersensitivity to any components of vorinostat or bortezomib~* has active hepatitis B or C, plasma cell leukemia, or is human immunodeficiency virus (HIV) positive~* has had prior treatment with vorinostat or histone deacetylase (HDAC) inhibitors

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vorinostat + Bortezomib (Type: EXPERIMENTAL): Participants undergo up to 3 successive 21-day treatment cycles. During Cycle 1, participants receive vorinostat (400 mg once daily \[QD\] on Days 1 through 14) + bortezomib (1.3 mg/m\^2 intravenous \[IV\] on Days 1, 4, 8, and 11). If that dose is not well tolerated, during Cycle 2 participants receive vorinostat (400 mg QD on Days 1 through 14) + bortezomib (1.0 mg/m\^2 IV on Days 1, 4, 8, and 11). If that dose is not well tolerated, during Cycle 3 participants receive vorinostat (300 mg QD on Days 1 through 14) + bortezomib (1.0 mg/m\^2 IV on Days 1, 4, 8, and 11).

Based on this trial design, predict the completion outcome and termination type (if applicable).